# **Oregon State Cancer Registry**





Definition of Reportable: Meets the criteria for inclusion in a registry. Reportable cases are cases that the registry/health care provider is required to collect and report. Reporting requirements for Oregon State Cancer Registry (OSCaR) are established by CDC/NPCR.

"Reportable List" includes all diagnoses to be reported to OSCaR.

#### 1. Malignant Histologies (In Situ and Invasive)

- **a.** Report all histologies with a behavior code of /2 or /3 in the ICD-O- Third Edition, Second Revision Morphology (ICD-O-3.2), except as noted in section 1.b. below
  - i. Early or evolving melanoma, in situ and invasive: As of 01/01/2021, early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.
  - **ii.** All GIST tumors are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2.
  - iii. Nearly all thymomas are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2. The exceptions are
    - Microscopic thymoma or thymoma, benign (8580/0)
    - Micronodular thymoma with lymphoid stroma (8580/1)
    - Ectopic hamartomatous thymoma (8587/0)
  - iv. Carcinoid, NOS of appendix is reportable. As of 01/01/2015, the ICD-O-3 behavior code changed from /1 to /3.
  - v. The following diagnoses are reportable (not a complete list)
    - Lobular carcinoma in situ (LCIS) of breast
    - Intraepithelial neoplasia, grade III

**Examples**: (Not a complete list. See 1.b.iii for PIN III.)

 Anal intraepithelial neoplasia III (AIN III) of the anus or anal canal (C210-C211)

Information from Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). SEER Program Coding and Staging Manual 2022. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute

### **Oregon State Cancer Registry**



- High grade biliary intraepithelial neoplasia (BilN III) of the gallbladder (C239)
- Laryngeal intraepithelial neoplasia III (LIN III) (C320-C329)
- Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III) breast (C500-C509)
- Pancreatic intraepithelial neoplasia (PanIN III) (C250-C259)
- Penile intraepithelial neoplasia, grade III (PeIN III) (C600-C609)
- Squamous intraepithelial neoplasia III (SIN III) excluding cervix (C53\_) and skin sites coded to C44
- Vaginal intraepithelial neoplasia III (VAIN III) (C529)
- Vulvar intraepithelial neoplasia III (VIN III) (C510-C519)

vi. Report Pilocytic/Juvenile astrocytomas; code the histology and behavior as 9421/3 Exception: The behavior is non-malignant when the primary site is optic nerve (C723).

**vii.** Non-invasive mucinous cystic neoplasm (MCN) of the pancreas with high grade dysplasia is reportable. For neoplasms of the pancreas, the term MCN with high grade dysplasia replaces the term mucinous cystadenocarcinoma, non-invasive.

viii. Mature teratoma of the testes in adults is malignant and reportable as 9080/3

ix. Urine cytology positive for malignancy is reportable for diagnoses in 2013 and forward

- Exception: When a subsequent biopsy of a urinary site is negative, do not report.
- Code the primary site to C689 in the absence of any other information
- Do not implement new/additional casefinding methods to capture these cases

Do **not** report cytology cases with ambiguous terminology

### b. Do not report (Exceptions to reporting requirements)

i. Skin primary (C440-C449) with any of the following histologies

Malignant neoplasm (8000-8005)

Information from Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). SEER Program Coding and Staging Manual 2022. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute

## **Oregon State Cancer Registry**



Epithelial carcinoma (8010-8046)

Papillary and squamous cell carcinoma (8050-8084)

Squamous intraepithelial neoplasia III (SIN III) (8077) of skin sites coded to C44

Basal cell carcinoma (8090-8110)

ii. In situ carcinoma of cervix (/2), any histology, cervical intraepithelial neoplasia (CIN III), or SIN III of the cervix (C530-C539)

Note: Collection stopped effective with cases diagnosed 01/01/1996 and later.

iii. Prostatic intraepithelial neoplasia (PIN III) (C619)

**Note**: Collection **stopped** effective with cases diagnosed 01/01/2001 and later.

### 2. Benign/Non-Malignant Histologies

a. Report benign and borderline primary intracranial and central nervous system (CNS) tumors with a behavior code of /0 or /1 in ICD-O-3 (effective with cases diagnosed 01/01/2004 to 12/31/2020) or ICD-O-3.2 (effective with cases diagnosed 01/01/2021 and later). See the table below for the specific sites.

**Note 1:** Benign and borderline tumors of the cranial bones (C410) are **not reportable**.

**Note 2:** Benign and borderline tumors of the peripheral nerves (C47\_) are **not reportable.** 

**b**. Report **Pilocytic/Juvenile astrocytomas**; code the histology and behavior as 9421/3when the primary site is C71\_

**Exception**: The behavior is non-malignant when primary site is optic nerve (C723).

- **c. Neoplasm and tumor** are reportable terms for intracranial and CNS because they are listed in ICD-O-3.2 with behavior codes of /0 and /1
  - i. "Mass" and "lesion" are not reportable terms for intracranial and CNS because they are not listed in ICD-O-3.2 with behavior codes of /0 or /1

Information from Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). SEER Program Coding and Staging Manual 2022. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute